Sandoz Group Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Richard Saynor
Chief executive officer
US$9.3m
Total compensation
| CEO salary percentage | 17.40% |
| CEO tenure | 7.3yrs |
| CEO ownership | n/a |
| Management average tenure | 4.1yrs |
| Board average tenure | 2.8yrs |
Recent management updates
Recent updates
Narrative Update • May 28
SDZ: Mixed Rating Shifts And Biosimilar Expansion Will Shape Future P/E
Analysts have adjusted the Sandoz Group price target slightly higher, with the updated fair value estimate moving from about CHF 66.01 to CHF 66.36 as they factor in modestly different assumptions for growth, margins and future P/E, following a mix of recent upgrades, initiations and target changes across the Street. Analyst Commentary Recent research on Sandoz Group reflects a mix of optimism and caution, with several firms adjusting ratings and price targets in different directions.Narrative Update • May 01
SDZ: Mixed Rating Shifts And Biosimilar Deals Will Shape Future P/E
The updated analyst price target for Sandoz Group has been revised by approximately CHF 1 higher, reflecting modestly adjusted assumptions around fair value, revenue growth, profit margins and future P/E as analysts balance recent target changes and rating shifts across major banks. Analyst Commentary Recent Street research around Sandoz Group shows a mix of optimism on the company’s long term potential and caution on how current pricing and expectations line up with execution risks.
Narrative Update • Apr 16
SDZ: Elevated Expectations Will Test Execution On Biosimilar Expansion Plans
Analysts have raised the Sandoz Group price target by roughly CHF 2 per share, reflecting a higher assumed fair value. This is supported by a series of recent CHF 3 to CHF 9 target increases from major banks and generally constructive views, despite some rating downgrades.
Narrative Update • Apr 01
SDZ: Future P/E Repricing And Biosimilar Expansion May Drive Re Rating
Analysts have lifted the price target for Sandoz Group from CHF 60.37 to CHF 81.99, citing recent initiations, upgrades and target increases that highlight a higher assumed future P/E multiple and slightly improved profit margin expectations, despite more measured revenue growth assumptions. Analyst Commentary Recent Street research on Sandoz Group presents a mixed picture, but there is a clear strand of optimism around execution, earnings quality and the scope for the shares to support higher valuation multiples.Narrative Update • Mar 18
SDZ: Mixed Rating Shifts And Biosimilar Expansion Will Shape Future P/E
Analysts have lifted the Fair Value estimate for Sandoz Group from CHF 62.57 to CHF 65.45. This reflects a series of higher Street price targets around CHF 62 to CHF 75 and updated assumptions for modestly higher revenue growth, a slightly lower profit margin profile, and a higher future P/E multiple.Narrative Update • Mar 04
SDZ: Mixed Rating Shifts And Biosimilar Pipeline Progress Will Shape Future P/E
Analysts have lifted their fair value estimate for Sandoz to about CHF 63, reflecting updated assumptions for slightly lower revenue growth, a higher profit margin and a modestly lower future P/E, along with recent mixed rating changes and higher price targets in the CHF 70 to CHF 75 range. Analyst Commentary Recent Street research on Sandoz shows a mix of optimism and caution, with price targets now clustering in the CHF 70 to CHF 75 range and ratings shifting closer to neutral.Narrative Update • Feb 18
SDZ: Richer Future P/E Assumptions Will Test Biosimilar Execution Confidence
Our latest narrative update on Sandoz Group reflects a higher implied fair value of CHF 58.42, up from CHF 52.75, supported by recent analyst price target increases and a willingness to assign a richer future P/E multiple. Analyst Commentary Recent Street research around Sandoz Group has centered on a series of price target revisions and at least one rating upgrade, which together frame how the analyst community is thinking about valuation, execution risk, and growth potential.Narrative Update • Feb 03
SDZ: Elevated Expectations Will Confront Ongoing Execution And Manufacturing Setbacks
Analysts have raised their average price target on Sandoz Group by CHF 3 to CHF 60, citing updated assumptions for revenue growth, profit margins and future P/E, in line with recent target increases from several major banks. Analyst Commentary Recent Street research on Sandoz Group has largely focused on recalibrating price targets to reflect updated views on revenue growth, profitability and valuation multiples.Narrative Update • Jan 20
SDZ: Rising Biosimilar Pipeline Will Face Ongoing Execution And Manufacturing Risks
Narrative Update The updated analyst price target for Sandoz Group reflects a modestly lower fair value estimate alongside slightly higher revenue growth and profit margin assumptions. Recent Street research citing price target moves to CHF 60 and CHF 70 indicates that analysts see room for the shares to better reflect these revised expectations.Narrative Update • Jan 06
SDZ: Elevated Biosimilar Ambitions Will Face Ongoing Execution And Manufacturing Risks
Analysts have lifted their average price targets on Sandoz Group into a CHF 49 to CHF 70 range, and our updated fair value of CHF 44.42 nudges slightly lower as higher assumed profit margins and revenue growth are offset by a reduced future P/E multiple. Analyst Commentary Recent Street research on Sandoz Group shows a cluster of higher price targets, with targets in the CHF 49 to CHF 70 range.Narrative Update • Dec 21
SDZ: Elevated Expectations Will Face Execution Risks In Biosimilars Expansion
Sandoz Group's analyst price target has been lifted by roughly CHF 6.50 to around CHF 60, as analysts now factor in stronger revenue growth, modestly higher profit margins, and a richer forward valuation multiple. Analyst Commentary Recent Street research has been broadly constructive on Sandoz Group, with several major firms lifting their price targets into the CHF 49 to CHF 60 range and maintaining positive ratings.Narrative Update • Dec 07
SDZ: Biosimilar Launch Execution Will Shape Future Multiple And Risk Balance
Sandoz Group’s analyst price target has been nudged higher, with fair value estimates rising by about CHF 1.10 to CHF 52.75 as analysts point to sustained revenue growth expectations and a modestly higher future P E multiple, despite slightly lower margin forecasts. Analyst Commentary Bullish analysts have recently raised their price targets into the CHF 55 to CHF 60 range, signaling growing confidence that Sandoz can sustain above market growth and support a higher valuation multiple.Narrative Update • Nov 23
SDZ: Sustained Revenue Momentum And Margin Focus Will Shape Fair Value Ahead
The analyst consensus price target for Sandoz Group has increased to CHF 60 from CHF 55. Analysts cite improved margin outlook and sustained revenue growth as key factors supporting the upward revision.Narrative Update • Nov 09
SDZ: Recent US Launch and European Expansion Will Influence Near-Term Performance
The average analyst price target for Sandoz Group has increased from CHF 50.33 to CHF 52.05, reflecting improved revenue growth forecasts and recent supportive analyst research updates. Analyst Commentary Recent analyst updates reflect a mix of optimism and caution regarding Sandoz Group's valuation, growth prospects, and execution.Narrative Update • Oct 26
Future Opportunities Will Be Unlocked Through Expanding Pipeline And Global Market Reach
The analyst consensus price target for Sandoz Group rose modestly, increasing from CHF 50.20 to CHF 50.33. Analysts cited stronger revenue growth and improving profit margins in their updated outlooks.Narrative Update • Oct 12
Biosimilar Pipeline And Global Expansion Will Unlock Future Opportunities
The analyst price target for Sandoz Group has increased by CHF 0.81. This reflects positive sentiment from analysts who cite strong revenue growth and continued profitability improvements as supporting factors.New Narrative • Aug 17
Biosimilar Pipeline And Global Expansion Will Unlock Future Opportunities
Key Takeaways Accelerated biosimilar launches, improved manufacturing, and strong market share are driving margin expansion and long-term profitability. Strategic focus on international growth and a robust product pipeline positions the company for sustainable earnings momentum.Analysis Article • Jun 25
Sentiment Still Eluding Sandoz Group AG (VTX:SDZ)
You may think that with a price-to-sales (or "P/S") ratio of 2.2x Sandoz Group AG ( VTX:SDZ ) is definitely a stock...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | US$9m | US$2m | US$914m |
| Sep 30 2025 | n/a | n/a | US$571m |
| Jun 30 2025 | n/a | n/a | US$227m |
| Mar 31 2025 | n/a | n/a | US$114m |
| Dec 31 2024 | US$8m | US$1m | US$0 |
| Sep 30 2024 | n/a | n/a | -US$4m |
| Jun 30 2024 | n/a | n/a | -US$8m |
| Mar 31 2024 | n/a | n/a | US$35m |
| Dec 31 2023 | US$2m | US$342k | US$77m |
Compensation vs Market: Richard's total compensation ($USD9.27M) is above average for companies of similar size in the Swiss market ($USD6.16M).
Compensation vs Earnings: Richard's compensation has increased in line with SDZ recently becoming profitable.
CEO
Richard Saynor (58 yo)
7.3yrs
Tenure
US$9,272,924
Compensation
Mr. Richard Saynor has been Chief Executive Officer at Sandoz International GmbH since July 15, 2019. Mr. Saynor served as Chief Executive Officer of Sandoz at Novartis AG since July 15, 2019 until 2023. H...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 7.3yrs | US$9.27m | no data | |
| Chief Financial Officer | 1.8yrs | US$10.58m | no data | |
| Chief Technology Officer | no data | no data | no data | |
| Chief Scientific Officer & President of Generics Development | 3.8yrs | no data | no data | |
| Head of Investor Relations | no data | no data | no data | |
| General Counsel & Chief Compliance Officer | 7.3yrs | no data | no data | |
| Chief People Officer | 3yrs | no data | no data | |
| Chief Manufacturing & Supply Officer and President of Generics Manufacturing and Supply | 4.3yrs | no data | no data | |
| Chief Commercial Officer | 6.3yrs | no data | no data | |
| President of North America | 5.3yrs | no data | no data | |
| Chief Transformation & Growth Officer | 2.8yrs | no data | no data | |
| President of Europe | 1.7yrs | no data | no data |
4.1yrs
Average Tenure
54yo
Average Age
Experienced Management: SDZ's management team is considered experienced (4.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Non-Executive Chairman | 3.2yrs | US$1.08m | 0.012% CHF 3.5m | |
| Independent Non-Executive Director | 2.1yrs | US$338.63k | 0.00058% CHF 164.6k | |
| Independent Non-Executive Director | 2.1yrs | US$290.34k | 0.00054% CHF 153.3k | |
| Independent Non-Executive Director | 2.8yrs | US$321.65k | 0.0018% CHF 516.6k | |
| Independent Non-Executive Director | 2.8yrs | US$351.25k | 0.00082% CHF 232.8k | |
| Independent Non-Executive Director | 2.8yrs | US$328.21k | 0.0034% CHF 979.3k | |
| Independent Non-Executive Vice Chairman | 2.8yrs | US$435.26k | 0.0031% CHF 888.4k | |
| Independent Non-Executive Director | 2.8yrs | US$290.34k | 0.00070% CHF 198.7k | |
| Independent Non-Executive Director | 2.8yrs | US$328.21k | 0.00079% CHF 224.2k | |
| Independent Non-Executive Director | 2.1yrs | US$346.90k | 0.00059% CHF 167.5k |
2.8yrs
Average Tenure
60.5yo
Average Age
Experienced Board: SDZ's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/31 09:39 |
| End of Day Share Price | 2026/05/29 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sandoz Group AG is covered by 38 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Emily Field | Barclays |
| James Gordon | Barclays |
| Sidhartha Modi | Barclays |